If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Auxilium Pharmaceuticals (AUXL) Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture XIAFLEX Also Meets ...

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...

After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...

MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...

DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...

-- Endo presents encore data of research evaluating the impact of PD on erectile function and female partners, as well as the efficacy of XIAFLEX® treatment -- DUBLIN, May 19, 2015 /PRNewswire/ -- ...

September 17, 2009 — The US Food and Drug Administration (FDA)'s Arthritis Advisory Committee voted unanimously (12 to 0) yesterday to recommend approval of collagenase clostridium histolyticum ...

DUBLIN, Oct. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) ...

MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his ...